Klotho Neurosciences Terminates Share Agreement with SkyBell, Enhances Focus on Longevity Research

Klotho Neurosciences Decides to End Share Exchange Agreement with SkyBell

On June 18, 2025, Klotho Neurosciences, Inc. (NASDAQ: KLTO) publicly announced the mutual termination of its Share Exchange Agreement with SkyBell Technologies, Inc. This decision marks a significant turning point for Klotho, enabling the company to enhance its focus on crucial therapeutic developments and longevity programs.

Key Highlights of the Termination

The termination of this agreement carries several notable benefits:

Elimination of Future Dilution

One of the principal advantages of this mutual decision is the cessation of any obligation for Klotho to issue new common stock to SkyBell. If the agreement had continued, it could have resulted in SkyBell holding as much as 90% of the company’s shares, which would have significantly diluted the interests of existing shareholders. The elimination of this potential future dilution allows Klotho to maintain its shareholder value by preserving its ownership structure.

No Liability Incurred

Furthermore, the termination ensures that neither Klotho nor SkyBell will incur any liabilities due to this agreement's end. This clean exit provides both companies a fresh start without the burden of previous commitments.

Refocused Strategy

With the conclusion of the Share Exchange Agreement, Klotho is set to refine its strategy and concentrate its resources on core business activities. Dr. Joseph Sinkule, CEO of Klotho, emphasized that this decision facilitates a more focused approach that will allow the company to devote time and capital toward advancing its key therapeutic programs. These programs specifically target neurodegenerative diseases and other age-related disorders, which are becoming more critical as populations age globally.

Klotho's Commitment to Therapeutics

Klotho Neurosciences is committed to developing innovative therapies that target the aging process and age-related illnesses. Their research is rooted in the exploration of the anti-aging human Klotho gene, which has shown promise in modifying and treating disorders such as Alzheimer's, ALS, and Parkinson's disease. By redirecting its focus and energy towards these avenues, Klotho aims not only to innovate but also to deliver vital breakthroughs in longevity and therapeutic treatment.

Dr. Sinkule expressed his dedication to discovering and creating transformative therapies for aging and age-related complications. He firmly believes that advancements in anti-aging gene and biologic therapies can effectively slow the aging process and decrease mortality linked to age-related organ failure. Klotho is rapidly approaching strategic milestones that aim to pave the way for longer, healthier human lifespans.

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. is a biogenetics firm that specializes in developing groundbreaking cell and gene therapies. Leveraging a valuable human protein derived from their patented form of the anti-aging Klotho gene (s-KL), Klotho aims to transform the treatment landscape for diseases associated with aging and neurodegeneration. The company utilizes novel gene promoters and delivery systems to enhance their therapy's effectiveness. Currently, Klotho's portfolio includes proprietary cell and gene therapy programs involving DNA and RNA therapeutics, along with genomics-based diagnostic assays.

As Klotho Neurosciences continues its journey toward innovative drug development, it remains committed to building shareholder value and enhancing treatment modalities that could redefine aging and longevity science. With a skilled team of professionals and advisors experienced in biopharmaceutical development and commercialization, Klotho is poised to make significant contributions to the healthcare ecosystem.

For further details about Klotho's initiatives and developments, interested parties can access additional information via their corporate website or contact investor relations.

This release contains forward-looking statements under the